By Cody R. Barnett, MRA Director of Communications
Join MRA on February 26, 2020 for an exciting half-day conference to learn about cutting-edge advances in melanoma, the research pipeline, and the latest in melanoma prevention and early detection. With options to participate in person or virtually, the forum will bring patients, survivors, and loved ones together with world-renowned melanoma clinicians and researchers to learn from each other, get support, and leave empowered.
12:00 pm – 1:00 pm — Lunch & Networking
1:00 pm – 1:10 pm — Welcome Remarks
Michael Kaplan – President & CEO, Melanoma Research Alliance
1:10 pm – 1:30 pm — Introductions: Who We Are & Why We Are Here
1:30 pm – 2:20 pm — The Melanoma Treatment Landscape
Learn where we are, where we’ve been, and where research is taking us.
Rizwan Haq, PhD, MD – Dana-Farber Cancer Institute
2:20 pm – 2:30 pm — Break
2:30 pm – 3:30 pm — Is it Hope or Hype?
We’ve all see headlines proclaiming the imminent cure for cancer, only to be let down after reading just a few lines. Learn how to separate hype from hope.
Liz Szabo – Kaiser Health News
Jason Luke, MD – University of Pittsburgh
3:30 pm – 4:00 pm — Ask the Expert: Animal Models
What role do animal models play in developing next-generation melanoma therapies?
Liz Patton, PhD – University of Edinburgh
4:00 pm – 4:15 pm — Break
4:15 pm – 5:45 pm — Looking Beyond 2020: The Next Decade of Melanoma Treatment
The melanoma treatment landscape has more options than ever. Hear from experts on emerging approaches gaining steam in clinical trials and the clinic.
Georgia Beasley, MD – Duke University
Stephanie L. Goff, MD – National Cancer Institute
Kenneth Grossman, MD, PhD – University of Utah
James Moon, PhD – University of Michigan
Antoni Ribas, MD, PhD – University of California, Los Angeles
Moderator: Marlana Orloff, MD – Thomas Jefferson University
5:45 pm – 6:00 pm — Closing & Wrap Up
6:00 pm – 7:30 pm — MRA Advocate & Researcher Reception
Registration is free, but space is limited!
This post was originally published by the Melanoma Research Alliance. It is republished with permission.